OSMI-1

Catalog No.S9835 Batch:S983502

Print

Technical Data

Formula

C28H25N3O6S2
Molecular Weight 563.64 CAS No. 1681056-61-0
Solubility (25°C)* In vitro DMSO 100 mg/mL (177.41 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description OSMI-1 is a cell-permeable O-GlcNAc transferase (OGT) inhibitor with IC50 of 2.7 μM for full length human OGT (ncOGT).
Targets
ncOGT [1]
(Cell-free assay)
2.7 μM
In vitro

OSMI-1 is cell-permeable and inhibits protein O-GlcNAcylation in several mammalian cell lines without qualitatively altering cell surface N- or O-linked glycans.[1]
In vivo

OSMI-1 acts as a potential chemosensitizer by enhancing DOX-induced cell death. The combination of DOX and OSMI-1 stimulates cell death, dramatically reducing cell proliferation and tumor growth in vivo using a HepG2 xenograft mouse model.[2]

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    CHO cells

  • Concentrations

    10 μM, 25 μM, 50 μM, 100 μM

  • Incubation Time

    24 h

  • Method

    CHO cells grown to 50-60% confluency are treated with OSMI-1, at the indicated concentrations for 24 hours. After treatment, cells are harvested and cell lysates are immunoblotted with the indicated antibodies.
Animal Study:

[2]
  • Animal Models

    5-week-old female BALB/c-Foxn1nu athymic nude mice

  • Dosages

    1 mg/kg, 5 mg/kg

  • Administration

    IV

Selleck's OSMI-1 has been cited by 2 publications

The GFPT2-O-GlcNAcylation-YBX1 axis promotes IL-18 secretion to regulate the tumor immune microenvironment in pancreatic cancer [ Cell Death Dis, 2024, 15(4):244] PubMed: 38575607
GFAT1/HBP/O-GlcNAcylation axis regulates β-catenin activity to promote pancreatic cancer aggressiveness [ Biomed Res Int, 2020, 2020:1921609] PubMed: 32149084

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.